Drug Profile
Leramistat - Istesso
Alternative Names: JNJ-7752; MBS-2320Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator University of Aberdeen
- Developer Istesso
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis; Rheumatoid arthritis
- Phase I Autoimmune disorders
- Discontinued Multiple myeloma; Ulcerative colitis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(Adjunctive treatment) in United Kingdom (PO, Capsule)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(Adjunctive treatment) in United Kingdom (PO, Suspension)
- 29 Jan 2024 Istesso completes a phase IIb trial for Rheumatoid arthritis in Bosnia-Herzegovina, Bulgaria, Chile, Czech Republic, Guatemala, Mexico, Poland, Serbia (PO) (NCT05460832) (EudraCT2020-005496-13)